On March 21, 2017, the Federal Court dismissed the applicants’ prohibition application under the Patented Medicines (Notice of Compliance) Regulations in connection with Apotex’s proposed generic dasatinib product. The court found Apotex’s invalidity allegations regarding Canadian Patent Nos. 2,366,932 and 2,519,898 to be justified.